CorFlow Selected to Present at EuroPCR 2018

CorFlow Selected to Present at EuroPCR 2018

Baar, Switzerland, May 15th 2018

CorFlow Therapeutics AG today announced that the company has been selected to present the Controlled Flow Infusion (CoFI™) technology during the EuroPCR conference in Paris, May 21st – 24th 2018.

The company will present the CoFI™ technology during three different sessions:

Monday May 21st @ 09:45 during The Innovators Day, Room Havane
“CorFlow Therapeutics – A new understanding of the coronary microcirculation to improve heart attack outcomes” presented by Jon H. Hoem, CEO & co-Founder, CorFlow Therapeutics AG, Baar, Switzerland

Wednesday May 23rd @ 15:00 in the “Out-of-the-Box Technologies” session, Room 252A / level 2
“Controlled flow infusion to diagnose real-time coronary vascular resistance correlating with cardiac MRI microvascular obstruction in an experimental occlusion-reperfusion model” presented by Dr. Robert S. Schwartz, M.D. & co-Founder, Minneapolis Heart Institute, Minneapolis, MN, USA

Wednesday May 23rd @ 15:15 in the “Novel approaches to coronary physiology” moderated e-poster session, Posters’ LAB / level 1
“Dynamic absolute microvascular function assessment: resistance and compliance in real time by controlled flow infusion” presented by Dr. Jonathan G. Schwartz, M.D., Sanger Heart & Vascular Institute, UNC Charlotte, Charlotte, NC, USA

CorFlow looks forward to present the latest scientific findings at the EuroPCR which is one of the leading conferences to discuss breakthrough advances in interventional cardiology.

CorFlow Therapeutics has since its foundation in June 2016 worked to document that the CoFI™ technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation in the cathlab fitting the workflow for acute heart attack (STEMI) patients.

CorFlow Therapeutics will present the recent findings using the CoFI™ technology during the EuroPCR conference in Paris, France, May 21-24.

The company is preparing to file the dossier for the First-in-Man clinical trials named the MOCA (Microvascular Obstruction with the CoFI™ System Assessment) trials. The MOCA I trial will investigate the safety and feasibility of the diagnostic component of the CoFI™ technology. The following MOCA II trial is a randomised controlled trial using adaptive design to investigate the effectiveness of intra-coronary drug delivery using the CoFI™ method and comparing this to current standard of care.

To support the development of its second generation devices and regulatory clearances, CorFlow will also initiate its A financing round during EuroPCR.

We look forward to see you in Paris!

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *

12 − 11 =